Prospective Evaluation of the Use of PET-CT in Hepatocarcinoma

Recruiting

• Conditions: Hepatocellular carcinoma; C04.588.274.623

• Registration Number: RBR-3vxgjsj
• Lead Sponsor: Fundação Antônio Prudente - AC Camargo Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-12
• Last Update Posted: 26 July 2023
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

A total of 30 patients diagnosed with established hepatocellular carcinoma will be prospectively included and analyzed with the 18F-PSMA (Fluorine-18 Prostate specific Membrane Antigen) PET/CT (Positron emission tomography) study

Exclusion Criteria

none

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the anomalous concentration of 18F-PSMA in the primary site (liver) as well as in secondary sites (metastases) Using the quantitative method with numerical measurement of the suv (standard uptake value) of the target lesions and jointly the qualitative analysis (visual comparison with normal biodistribution areas).<br>

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are not expected.